Cardiology Service, Complejo Hospitalario de Santiago de Compostela, CIBERCV, Santiago de Compostela, A Coruña, Spain.
Cardiology Service, Complejo Hospitalario de Santiago de Compostela, CIBERCV, Santiago de Compostela, A Coruña, Spain.
Hellenic J Cardiol. 2022 Jul-Aug;66:1-10. doi: 10.1016/j.hjc.2022.04.007. Epub 2022 May 2.
Renal dysfunction in patients with ST-elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention (pPCI) indicates a poor long-term prognosis. However, the prognostic value of the improvement or stabilisation of renal function during follow-up has not yet been assessed. This study aimed to investigate the long-term predictive impact of the improvement or stabilisation of renal function after one year of follow-up in patients with STEMI undergoing pPCI with renal dysfunction at discharge.
This prospective, single-centre cohort study included 2170 consecutive patients with STEMI who underwent pPCI. The glomerular filtration rate (GFR) was determined at hospital discharge and one-year follow-up. The median clinical follow-up was 72 months.
Among the 2004 patients, 393 (19.6%) had a GFR <60 ml/min, and 1611 (80.4%) had a GFR ≥ 60 ml/min at discharge. Among patients with GFR <60 ml/min, data at one-year follow-up were available for 342. Of these patients, 127 (32%) showed improvement in renal function (defined as improvement in the Kidney Disease Improving Global Outcomes (KDIGO) chronic kidney disease (CKD) classification), 47 (12%) showed worsening of renal function (defined as worsening of the KDIGO CKD classification), and 168 (43%) showed no category changes. Improvement or stabilisation of GFR at one year of follow-up was associated with a reduction of major adverse cardiovascular events (MACE) [HR 0.51, 95% CI: 0.35-0.75, p = 0.001] and all-cause mortality [HR 0.54, 95% CI: 0.34-0.84, p = 0.007] during follow-up.
The improvement or stabilisation of renal function at one-year follow-up in patients with STEMI and renal dysfunction is associated with a better long-term prognosis.
行直接经皮冠状动脉介入治疗(pPCI)的 ST 段抬高型心肌梗死(STEMI)患者发生肾功能障碍提示预后不良。然而,在随访期间肾功能改善或稳定的预后价值尚未得到评估。本研究旨在探讨在 pPCI 后一年随访期间肾功能改善或稳定的 STEMI 合并肾功能障碍患者的长期预测影响。
这是一项前瞻性、单中心队列研究,纳入了 2170 例连续 STEMI 患者行 pPCI。在出院和随访 1 年时确定肾小球滤过率(GFR)。中位临床随访时间为 72 个月。
在 2004 例患者中,393 例(19.6%)的 GFR<60 ml/min,1611 例(80.4%)的 GFR 在出院时≥60 ml/min。在 GFR<60 ml/min 的患者中,1 年随访的数据可用于 342 例患者。这些患者中,127 例(32%)肾功能改善(定义为肾脏病改善全球结局(KDIGO)慢性肾脏病(CKD)分类改善),47 例(12%)肾功能恶化(定义为 KDIGO CKD 分类恶化),168 例(43%)无类别变化。1 年随访时 GFR 改善或稳定与主要不良心血管事件(MACE)减少相关[HR 0.51,95%CI:0.35-0.75,p=0.001]和全因死亡率[HR 0.54,95%CI:0.34-0.84,p=0.007]。
在 STEMI 和肾功能障碍患者中,随访 1 年时肾功能改善或稳定与更好的长期预后相关。